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Abstract
BACKGROUND: Melanoma inhibitory activity 2 (MIA2) is a novel gene of the MIA gene family. The
selective expression of MIA2 in hepatocytes is controlled by hepatocyte nuclear factor (HNF) 1 binding
sites in the MIA2 promotor. In contrast, in most hepatocellular carcinomas (HCC) MIA2 expression is
down-regulated or lost. AIM: In this study we examined the regulation and functional role of MIA2 in
hepatocancerogenesis. METHODS AND RESULTS: In HCC cell lines and tissues HNF-1 expression
was lower than in primary human hepatocytes (PHH) and corresponding non-tumorous tissue,
respectively, and correlated significantly with the down-regulation of MIA2 expression. Re-expression
of HNF-1 in HCC cells reinduced MIA2 in HCC cells to similar levels as found in PHH. Further, MIA2
was re-expressed in HCC cell lines by stable transfection, and the generated cell clones revealed a
strongly reduced invasive potential and proliferation rate in vitro. In line with these findings treatment of
HCC cells with recombinant MIA2 inhibited proliferation and invasion. In nude mice MIA2
re-expressing HCC cells grew significantly slower and revealed a less invasive growth pattern.
Immunohistochemical analysis of a tissue microarray containing HCC and corresponding non-cancerous
liver tissue of 85 patients confirmed reduced MIA2 expression in HCC. Furthermore, MIA2 negative
HCC tissue showed a significantly higher Ki67 labelling index and loss of MIA2 expression correlated
significantly with more advanced tumour stages. CONCLUSION: This study presents MIA2 as an
inhibitor of HCC growth and invasion both in vitro and in vivo, and consequently, as a tumour
suppressor of HCC. Further, our findings indicate a novel mechanism, how loss of HNF-1 expression in
HCC affects tumorigenicity via down-regulation of MIA2.
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ABSTRACT 
 
 
Background: Melanoma Inhibitory Activity 2 (MIA2) is a novel gene of the MIA gene 
family. The selective expression of MIA2 in hepatocytes is controlled by hepatocyte 
nuclear factor (HNF) 1 binding sites in the MIA2 promotor. In contrast, in most 
hepatocellular carcinomas (HCC) MIA2 expression is downregulated or lost. 
Aim: In this study we examined the regulation and functional role of MIA2 in 
hepatocancerogenesis. 
Methods and results: In HCC-cell lines and tissues HNF-1 expression was lower 
than in primary human hepatocytes (PHH) and corresponding non-tumorous tissue, 
respectively, and correlated significantly with the downregulation of MIA2 expression. 
Re-expression of HNF-1 in HCC cells reinduced MIA2 in HCC cells to similar levels 
as found in PHH. Further, MIA2 was re-expressed in HCC cell lines by stable 
transfection, and the generated cell clones revealed a strongly reduced invasive 
potential and proliferation rate in vitro. In line with these findings treatment of HCC 
cells with recombinant MIA2 inhibited proliferation and invasion. In nude mice MIA2 
re-expressing HCC cells grew significantly slower and revealed a less invasive 
growth pattern. Immunohistochemical analysis of a tissue microarray containing 
HCC and corresponding non-cancerous liver tissue of 85 patients confirmed reduced 
MIA2 expression in HCC. Furthermore, MIA2 negative HCC tissue showed a 
significantly higher Ki67 labelling index and loss of MIA2 expression correlated 
significantly with more advanced tumour stages.  
Conclusion: This study presents MIA2 as an inhibitor of HCC growth and 
invasion both in vitro and in vivo, and consequently, as a tumour suppressor of 
HCC. Further, our findings indicate a novel mechanism, how loss of HNF-1 
expression in HCC affects tumorigenicity via downregulation of MIA2. 
 
INTRODUCTION 
Primary hepatocellular carcinoma (HCC) is the fifth most frequent cancer and the 
third most common cause of cancer-related deaths in the world with an increasing 
incidence in the US, mainly due to HCV, HBV and alcoholic liver disease 1. 
Histopathological and molecular findings suggest that HCC develops through a 
multistep process with accumulating genetic alterations. However, the molecular 
pathogenesis of HCC is still not well understood. While new therapeutic strategies 
have significantly improved survival of patients with tumours detected at early 
stages, the majority of patients are still diagnosed at an advanced stage and their 
prognosis remains poor 2;3. These findings highlight the need for discovery of 
molecular markers and targets for improved diagnosis and treatment, respectively, of 
HCC. 
 
Recently, we identified a new gene, melanoma inhibitory activity 2 (MIA2), and 
mapped the gene locus to human chromosome 14q13 4. MIA2, together with MIA, 
OTOR and TANGO, belongs to the novel MIA gene family sharing important 
structural features, significant homology and similar genomic organization 5;6. In 
contrast to the other family members, MIA2 contains an additional C-terminal 
region of 422 amino acids without any homology to known proteins 4. Interestingly, 
the four members of the MIA gene family differ entirely with respect to their 
expression patterns. In contrast to MIA, which is exclusively expressed in cartilage 
but not in any other non-neoplastic tissue 7, and OTOR, which shows a highly 
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restricted expression pattern in cochlea, eye and cartilage 8, the novel MIA related 
gene MIA2 is expressed exclusively in the liver 4;5. Hepatocytes were identified as 
the cellular source of MIA2 expression and promoter studies analyzing 
transcriptional regulation of MIA2 revealed an HNF-1 binding site controlling 
hepatocyte specific expression. However, in HCC cell lines and tissues we 
observed a strong downregulation or even loss of expression of MIA2 9. 
 
Based on these previous findings, the aim of this study was to investigate the 
regulation, functional role and clinical importance of MIA2 in 
hepatocancerogenesis. 
 
MATERIALS AND METHODS
 
 
Cells and cell culture 
The HCC cell lines HepG2 (ATCC HB-8065), PLC (ATCC  CRL-8024), HuH-7 (JCR 
B0403) and Hep3B (ATCC HB-8064) were used. Cells were maintained in DMEM 
supplemented with penicillin (400 U/ml), streptomycine (50 µg/ml), L-glutamine (300 
µg/ml) and 10% fetal calf serum (FCS; Sigma, Deisenhofen, Germany) and 
passaged at a 1:5 ratio every three days.  
MIA2 expressing cell clones were established by stable transfection of HepG2 cells 
with a MIA2 expression plasmid 4. Plasmids were co-transfected with pcDNA3 
(Invitrogen, NV Leek, The Netherlands) containing the selectable marker for 
neomycin resistance. Transfections were performed using Lipofectamine Plus 
(Invitrogen). Mock controls received pCDNA3 alone. 
Primary human hepatocytes (PHH) were isolated and cultured as previously 
described 10;11. 
 
Tumourous and non-neoplastic human tissues 
HCC tissue and non-neoplastic liver tissue of the same patient were obtained from 
10 HCC patients undergoing partial hepatectomy. Tissue samples were immediately 
snap frozen and stored at -80°C. Informed consent was obtained from all patients 
and the study was approved by the local Ethics Committee. 
 
HCC tissue microarray (TMA) 
A tissue microarray (TMA) was constructed as described previously 12 13;13and 
contained 85 formalin fixed, paraffin-embedded human HCC tissues and  
corresponding non-neoplastic liver tissues of the same patient (in 80 cases). 
Samples were retrieved from the surgical pathology files of the Institute of Pathology 
of the University of Regensburg, covering a period of 12 years (1993 to 2005). All 
patients were treated with surgical resection or liver transplantation. There were 69 
(81.2%) males and 16 (18.8%) females with a median age of 61 years (range 20-85 
years). Alcohol related liver disease was defined if long lasting excessive alcohol 
consumption (at least 80g/d in man and 40g/d in women for more than 10 years) was 
reported. In 32 patients (37.6%) no underlying cause of liver disease was found or 
could be defined, respectively. In all of these patients chronic viral hepatitis was 
excluded by testing for hepatitis B surface antigen, anti-HBc and third-generation 
hepatitis C antibody ELISA. However, it may be difficult to retrieve valid information 
on the amount and duration of alcohol consumption in retrospective studies, 
especially in patients with alcohol-related diseases as cirrhosis. In most cases, data 
stated by the patients or their relatives tend to be lower than the actual amount 
consumed, making it more than likely that the percentage of HCC patients with 
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alcohol abuse was actually higher than reported in our study. Further 
clinicopathological patient characteristics are summarized in table 1.   
Informed consent was obtained from all patients and the study was approved by the 
local Ethics Committee. 
 
Tumour cell inoculation and measurement of tumour growth in NMRI (nu/nu) mice  
A model of inoculation of tumour cells into NMRI (nu/nu) mice to monitor tumour 
growth in vivo was performed as described previously 14. Briefly, HCC cell clones 
were harvested after incubation with PBS containing 0.05% trypsin and 0.04% EDTA 
(Sigma). Tumour cells were washed twice with serum free DMEM (Dulbecco’s 
modified Eagle medium; Gibco) at room temperature and resuspended in DMEM at 
a concentration of 1x107 cells/ ml. 
For each of the four tumour cell lines a group of 10 NMRI (nu/nu) mice with a mean 
body weight of 32 g was formed. All mice were injected subcutaneously with a cell 
suspension of 0.1 ml containing 1x106 cells of a single cell line. Tumour growth 
kinetics were recorded on a regular basis by measurement of tumour diameters at 
the inoculation site (region of the thoracic mammary fat pad) with an electronic 
caliper. Tumour areas were calculated as the product of two perpendicular 
diameters, one measured across the greatest width of the tumour. For ethical 
reasons the mice were killed at day 15 after the first tumours underwent ulceration, 
and the tumours were taken out and stored for subsequent analysis. 
 
Expression analysis 
Isolation of total cellular RNA from cultured cells and tissues and reverse 
transcription were performed as described previously 15. Quantitative real time-
PCR was performed with specific primers for MIA2 9 and HNF-1 (HNF-1 forward: 
5’- CCT GTC CCA ACA CCT CAA CAA; HNF-1 reverse: 5’- TCT CTC GCT CCT 
CCT TGC TA) applying LightCycler technology (Roche, Mannheim, Germany) as 
described 9. 
 
Protein analysis  
Protein extraction and Western blotting were performed as described previously 16, 
applying the following primary antibodies: polyclonal anti-MIA2 antibody 9, or anti-ß-
actin antibody (Sigma). 
Immunohistochemical staining of 5µm sections of the TMA blocks was performed 
using polyclonal anti-MIA2 antibody and an indirect immunoperoxidase protocol 
according to the LSAB2-kit (Dako, Hamburg, Germany) as described 9. A surgical 
pathologist (F.B.) performed a blinded evaluation of the stained slides. Staining 
intensity was estimated using a semi quantitative three-step scoring system (0-2+): 
0, negative; 1+, weak positive; 2+, strong positive. In consideration of the small 
amount of tissue of each individual tumour on the TMA, even weak MIA2 
immunoreactivity (1+) was considered positive.  
MIB1 was analyzed applying anti-Ki67 antibody (rabbit monoclonal, clone MIB1; 
Dako; 1:10, final concentration 5 µg/ml).  
Antibody binding was visualized using AEC-solution (LSAB2-Kit, Dako Cytomation 
GmbH, Hamburg, Germany).  Finally, the tissues were counterstained by hemalaun. 
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Expression of recombinant MIA2 protein 
The MIA2 cDNA was cloned into the vector pIVEX2.3-MCS (Roche Applied 
Science). The expression vector was used in the rapid translation system, a cell-free 
E.coli-based protein transcription/translation system (Roche Applied Science) 
following the manufacturer's description. The correct expression of rhMIA2 was 
analyzed by western blotting. 
 
Transfection of HCC cell lines 
Applying the Lipofectamin plus method (Invitrogen, Carlsbad, USA) small interfering 
RNA (siRNA; Hs_TCF1_1 HP siRNA from Qiagen, Hilden, Germany) was transiently 
transfected into HCC cells to deplete HNF-1 expression. 
 
Cell proliferation assays 
Cell proliferation was measured using the XTT assay (Roche, Mannheim,  
Germany) as described 15;17. 
 
Invasion assays 
Invasion assays were performed using the BD BioCoat™ Matrigel™ Cell 
Environments, Invasion Chambers (BD Biosciences, Discovery Labware, Bedford, 
MA, USA) as described 17.  
 
Apoptosis assays 
For detection of apoptosis, cells were stained simultaneously with FITC-conjugated 
Annexin V and propidium iodide (PI) (both from Pharmingen) as described previously 
11
. Total numbers of apoptotic cells were determined by calculation of Annexin V+ 
and PI- cells together with Annexin V+ and PI+ cells. Analysis of data was performed 
using the software WinMDI (Version 2.8, http://facs.scripps.edu). 
 
Cell cycle analysis 
Nuclear DNA content was measured by using propidium iodide (PI) staining and 
fluorescence-activated cell sorting (FACS) analysis as described previously 18. 
Briefly, 106 cells were fixed in ice-cold methanol (70%) for 1 h on ice, washed twice 
with PBS, and resuspended in PBS. Fixed cells were treated with RNase (0.01 
mg/ml; Roche Molecular Biochemicals) for 30 min at 37 °C, stained with 50 µg/ml 
propidium iodine (PI; Sigma), and kept in the dark on ice for 30 min before analysis. 
Cell cycle analysis was carried out using an EPICS XL-MCL flow cytometer (Coulter 
Immunotech). Data were analyzed with the Multicycle software (Becton Dickinson, 
Heidelberg, Germany).  
 
Statistical analysis 
P values < 0.05 were considered significant. Statistical analyses were performed 
using SPSS version 10.0 (SPSS, Chicago, IL, USA).  
Results are expressed as mean ± SD (range) or percent. Comparison between 
groups was made using the Student's unpaired t-test. Correlation between 
parameters was calculated with the Spearman test. Contingency table analysis and 
two-sided Fisher's exact tests were used to study the statistical association between 
clinico-pathological and immunohistochemical variables.  
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RESULTS 
 
Reduced HNF-1 expression in HCC causes downregulation of MIA2 
Initially, we wanted to study the molecular mechanisms responsible for the strong 
reduction or loss of MIA2 expression that we have recently described in human 
HCC cell lines in vitro and HCC tissue in vivo 9. Since we have previously shown 
the regulation of MIA2 expression by HNF-1 4, we started to analyze the 
expression of this transcription factor in four different HCC cell lines compared to 
primary human hepatocytes (figure 1A). Interestingly, strong reduction of HNF1 
mRNA expression was found in all four HCC cell lines. Similarly, analysis of HNF1 
mRNA expression in tumor tissue of ten HCC patients revealed a reduction of 
HNF-1 expression in all cases as compared to corresponding non-neoplastic liver 
tissue. Overall, a 6.4±2.1-fold reduction was observed in HCC-tissue (figure 1B). 
As previously shown, MIA2 was also downregulated in all ten HCC-samples 
(9.9±4.5-fold), and reduction of HNF1 expression correlated significantly with the 
downregulation of MIA2 expression in HCC tissues (r=0.71; p=0.023) (figure 1C). 
To further analyze whether reduced HNF-1 expression levels are responsible for 
the downregulation of MIA2 expression in HCC, we transiently transfected HCC 
cell lines with an expression plasmid for HNF-1, and, subsequently, analyzed 
MIA2 mRNA expression in comparison to mock transfected and non-transfected 
controls. Transfection of HNF-1 was sufficient to reinduce MIA2 mRNA expression 
in HCC cells to similar levels as found in primary human hepatocytes. Figure 1D 
depicts results obtained with HepG2 cells. In a complementary approach, 
depletion of HNF-1 expression in HepG2 cells using small interfering RNA 
(siRNA) resulted in a significant downregulation of MIA2 expression compared to 
siRNA control and cells non-transfected controls (Fig. 1E). According data were 
obtained also with the other HCC cell lines studied (data not shown). In summary, 
these findings indicate, that reduced MIA2 expression in HCC may be caused by 
loss of HNF-1 expression in HCC. 
 
Re-expression of MIA2 in HCC cells 
To gain insight into the functional role of the downregulation of MIA2 in HCC, MIA2 
was re-induced in the HCC cell line Hep3B by stable transfection with a MIA2 
expression vector containing the full-length MIA2 cDNA under the control of the 
cytomegalovirus (CMV) promotor (clone 1 and 2). The vector without an insert was 
used as a control (mock). Quantitative RT-PCR analysis revealed a strong induction 
of MIA2 mRNA expression in both cell clones, whereas no (change of) MIA2 
expression was seen in mock transfected cell clones (figure 2A). Upregulation of 
MIA2 expression in the cell clones was confirmed on the protein level by western blot 
(figure 2B). Of note, changes in MIA2 mRNA expression match changes observed 
on the protein level. Immunofluorscence analysis confirmed re-expression of MIA2 in 
clone 1 (figure 2C) and clone 2 (data not shown).  
 
Functional changes after MIA2 re-expression in HCC cells in vitro 
To further characterize the role of MIA2 in HCC cells, we performed functional in 
vitro assays with MIA2 expressing cell clones in comparison to mock-transfected 
cells and the parental cell line. 
Proliferation was significantly impaired in MIA2 re-expressing cell clones (figure 3A). 
Based on this finding, we performed FACS analysis of propidium iodide-stained 
MIA2 expressing cell clones and control cells to investigate the cell cycle. It 
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appeared that the fraction of MIA2 cell clones that retained in the G0/G1 phase 
(clone 1 (c1): 35.9±1.9 % and clone 2 (c2): 38.8±2.2) was significantly higher than 
the fraction found within both mock-transfected (24.1±1.1%; p=0.032 vs. c1, and 
p=0.026 vs. c2) and non-transfected control cells (26.2±1.2%; p=0.048 vs. c1, and 
p=0.036 vs. c2). Further, FACS analysis revealed that less MIA2 re-expressing cells 
were in the S-phase (c1: 32.2±1.2% and c2: 25.0±0.6%) as compared to mock-
transfected controls (39.4±1.2%; p=0.047 vs. c1, and p=0.008 vs. c2),  while the 
percentage of cells detected in the G2/M-phase did not differ significantly between 
MIA2 cell clones and controls. 
Further, annexin V/propidium iodide-FACS analysis revealed only marginal apoptosis 
(<3%) in both MIA2 expressing cell clones and control cells, respectively, indicating 
that MIA2 expression does not affect apoptosis in HCC cells in vitro (figure 3C). 
To get further insight into the functional role of MIA2 we performed matrigel invasion 
assays. Interestingly, HCC cells stably transfected with MIA2 displayed significantly 
decreased invasiveness compared to mock transfected and non-transfected control 
cells (figure 3D).  
To confirm the functional effects of MIA2 on HCC cells and to get first insights into a 
potential therapeutic application of MIA2, HCC cells were treated with recombinant 
MIA2 (rMIA2). Addition of rMIA2 revealed the same inhibitory effect on cell 
proliferation (figure 3E) and invasion (figure 3F) as found in the stably MIA2 
expressing cell clones (figure 3A and 3D). 
 
Tumorigenicity of MIA2 re-expressing HCC cells in vivo
  
To test the effect of MIA2 on tumour growth in vivo HCC cells stably expressing 
MIA2 were injected subcutaneously into nude mice, revealing significantly impaired 
growth compared to mock or non-transfected cells (figure 4A). Ten days after 
injection of the HCC cells all mice from the mock and non-transfected control groups 
but only 6 of 10 (clone 1) and 4 of 10 (clone 2), respectively, animals from the MIA2 
re-expressing groups developed tumours. After 15 days, also all mice from the clone 
1 group and 6 mice from the clone 2 group developed tumours, however, these 
tumours were significantly smaller than from the other two groups (17.7±5.5 mm3 
(clone 1) and  7.9±3.1 mm3 (clone 2) vs. 57.5±12.1 mm3 (non-transfected) and 
59.8±14.9 mm3 (mock); p=0.017 (clone 1) and p=0.003 (clone 2) in comparison to 
mock, and p=0.008 (clone 1) and p=0.0009 (clone 2) in comparison to non-
transfected cells). These data indicate that rescue of MIA2 expression in HCC cells 
inhibits proliferation of HCC cells in vivo. 
Furthermore, histopathological analysis revealed that tumours developed from MIA2 
re-expressing HCC cells showed diffuse and invasive growth, while tumours from 
mock or non-transfected cells showed a more nodular growth. Representative 
pictures are shown in figure 4B.  
In summary and in line with the in vitro results, data obtained in nude mice indicate 
that reduced MIA2 expression in HCC cells induces tumorigenicity of HCC cells. 
 
MIA2 expression in human HCC 
Next, we analyzed MIA2 protein expression in a series of 85 HCC patients and 
corresponding non-tumourous tissue of the same patients (n=81) using tissue 
microarray technology. Investigation of MIA2 protein expression was informative in 
all 85 HCC tissue specimens and in 98.8% (80/81) of non-tumourous tissue 
samples, respectively. The clinico-pathological features and immunohistochemical  
results of the HCC tumour cohort are summarized in table 1. 
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Table 1:
 
MIA2 immunoreactivity (IR) in HCC-tissue of 85 patients in relation to 
clinico-pathological characteristics and proliferation rate.  
 
Variable       
    MIA2 IR   
  
Categorizatio
n n %   negative 
score 
1+ 
score 
2+ 
p* 
    
 
       
Clinico-pathological characteristics 
       
  
          
Age at diagnosis          
  <60 years 39 45.9  16 19 4 0.217 
  ≥60 years 46 54.1  12 24 10   
         Gender           
  female 16 18.8  9 6 1 0.095 
  male 69 81.2  19 37 13   
        Tumour stage          
  pT1 13 15.3  2 4 7 0.036 
  pT2 25 29.4  10 12 3   
  pT3 41 48.2  13 24 4   
  pT4 3 3.5  1 2 0   
  nd 3 3.5  2 1 0   
        Histological grade          
  G1 29 34.1  12 14 3 0.407 
  G2 48 56.5  12 26 10   
  G3 8 9.4  4 3 1   
         Aetiology           
  HBV 9 10.6  5 4 0 0.131 
  HCV 7 8.2  0 6 1   
  alcohol 34 40.0  10 19 5   
  others 3 3.5  2 0 1   
  unknown 32 37.6  11 14 7   
         Tumor size           
  ≤ 5 cm 36 42.4  10 18 8 0.323 
  > 5 cm 30 35.3  9 18 3   
  nd 19 22.4  9 7 3   
  
  
 
       
Proliferation rate (MIB1-Index)         
  ≤ 5% 40 47.1  7 23 10 0.008 
  > 5% 45 52.9  21 20 4   
      
  
          
* Fisher's exact test (2-sided); bold face representing p-values <0.05. 
(nd: no data available; IR: immunoreactivity)  
 
 
In 32.9% (28/85) of the HCC, no MIA2 expression was detectable. In contrast, MIA2 
protein expression (1+ or 2+) was found in all (n=80) non-cancerous tissue samples. 
 group.bmj.com on February 19, 2010 - Published by gut.bmj.comDownloaded from 
Hellerbrand  et al.: Functional role of MIA2 in HCC 9
Noteworthy, in 62.5% (50/80) of cases the MIA2 staining signal was lower in HCC as 
in corresponding non-tumorous liver tissue. Representative MIA2 immunostaining 
patterns are shown in figure 5A. Figure 5B summarizes the immunohistochemistry 
results for HCC and surrounding non-cancerous liver tissue on the TMA. MIA2 was 
significantly reduced in HCC (p<0.0001) compared to non-cancerous tissue.  
Matched data of mRNA expression and semiquantitative protein expression 
analyzed on the microarray were available from ten HCC patients. In all cases MIA2 
mRNA expression was reduced in HCC compared to non-tumorous liver tissue 
(41.0±9.6; p=0.0002). MIA2 mRNA expression was significantly more downregulated 
in five HCC cases, where also immunohistochemistry (IHC) revealed downregulation 
of MIA2 protein expression (21.1±11.4%) compared to five cases, where the MIA2 
immunosignal appeared similar in HCC and non-tumourous tissue (60.9±9.0%; 
p=0.026). These findings indicate that strong downregulation of MIA2 in HCC is 
accurately detected by IHC. On the other hand, less pronounced differences 
between HCC and non-tumorous liver tissue may be missed, and probably, MIA2 is 
downregulated in even more cases than now shown by immunohistochemistry. 
For descriptive data analysis, all relevant variables were compared with MIA2 IHC 
(table 1). Loss of MIA2 immunoreactivity was significantly associated with higher 
tumour stage (p=0.036). 
Furthermore, MIA2 negative HCC had a significant higher proliferation rate (MiB-1 
Index) compared to MIA2 positive HCCs (p=0.008; figure 5C). 
No correlation could be found with MIA2 expression and age, gender, histologic 
grade, size and aetiology of the underlying liver disease.  
 
DISCUSSION 
 
Recently, we identified a novel member of the MIA gene family, MIA2 and 
described tissue-specific expression in hepatocytes 4. Furthermore, we showed, 
that MIA2 is downregulated or lost in HCC 9. In this study, we demonstrate that 
loss of the transcription factor HNF-1 causes at least in part the transcriptional 
downregulation of MIA2 in HCC. Furthermore, we show that restoration of MIA2 
expression in HCC cells markedly inhibits growth and invasion both in vitro and in 
vivo. Additionally, we find that the loss of MIA2 expression is associated with 
higher tumour stage and tumour cell proliferation. Thus, this work provides direct 
evidence that MIA2 can be considered as a tumour-suppressor in HCC. 
Furthermore, our data indicate that MIA2 is a potential marker for HCC prognosis 
as well as an attractive therapeutic target.  
 
So far, we can only speculate on the molecular mechanisms how MIA2 exhibits its 
anti-tumourigenic effects. MIA2 is exclusively expressed in hepatocytes and 
analysis of the amino acid sequence of MIA2 as well as preliminary experiments 
analyzing the supernatant of hepatocytes indicate that MIA2 is a secreted protein 
(unpublished observation). Noteworthy, treatment of HCC cells with recombinant 
MIA2 exhibited similar effects on proliferation and invasiveness as re-expression 
of MIA2 by stable expression. This finding indicates that MIA2 acts at least in part 
in an autocrine fashion. In further studies, potential receptor(s) as well as 
downstream signalling pathways have to be determined. Furthermore, the 
therapeutic potential of MIA2 has to be further investigated. 
Previously, we have shown that hepatic MIA2 expression is increased in patients 
with liver fibrosis or cirrhosis, respectively 4. Furthermore, we demonstrated that 
transforming growth factor-beta (TGF-β) induced MIA2 expression in hepatocytes 
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in vitro 4, and it is well known that TGF-β signalling is deranged in HCC. 
Therefore, it may be speculated that impaired TGF-β signalling contributes to the 
reduced MIA2 transcriptional activity in cancerous liver tissue. 
Furthermore, we have demonstrated that hepatocyte specific expression of MIA2 
is controlled by HNF-1 binding sites in the MIA2 promotor. HNF-1 belongs to the 
liver-enriched transcription factors (LETFs) which have been identified to bind to 
the promotor or enhancer regions of various hepatic functional genes. Several 
studies have indicated that HNF1 participates in the control of cytodifferentiation 
and transcriptional alteration of this factor has been observed between normal and 
cancerous tissue 19;20. Our finding of reduced HNF-1 expression in HCC cell lines 
and tissues is in accordance with these previous studies. However, it was once 
reported that expression of HNF-1 was increased in 4 of 6 HCC samples 21. The 
discrepancy between our results and this previous report may be explained by the 
relatively small number of the tumour samples analyzed. A tumour-suppressor 
function for HNF-1 is supported by the phenotypes observed in two HNF1 
deficient mouse strains. These mice have either a pronounced liver enlargement 
caused by an increased proliferation of hepatocytes 22 or a liver enlargement with 
central lobular hypertrophy and degeneration of individual hepatocytes 23. 
Furthermore, germline mutations of transcription factor (tcf) 1 gene encoding 
HNF1 have been found in hepatic adenomas 24. 
However, so far a direct effect of HNF-1 on the tumorigenicity of cells has not 
been suggested. Here, our findings indicate a novel mechanism, how (loss of) 
HNF-1 expression in HCC affects tumorigenicity via (down)regulation of MIA2. 
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FIGURE LEGENDS 
Figure 1: Reduced HNF1 expression in HCC is causing downregulation of MIA2  
HNF-1 mRNA expression was determined by quantitative RT-PCR in (A) primary 
hepatocytes (PHH) and four HCC cell lines (HepG2, PLC, Hep3B, HUH-7), and (B) 
ten human HCC samples and corresponding non-tumorous (nt) liver tissue samples. 
(C) Correlation of HNF-1 and MIA2 mRNA expression in the ten HCC tissue samples 
analyzed. MIA2 mRNA expression was determined by quantitative RT-PCR in (D) 
HepG2 cells transiently transfected with an expression plasmid for HNF1 (HNF1), 
mock transfected (pCMX) and non-transfected controls (wt), and (E) HepG2 cells 
transiently transfected with HNF-1 siRNA nucleotides, scrambled siRNA control and 
non-transfected controls (wt). In both experiments MIA2 mRNA expression is 
depicted in relation to primary human hepatocytes (PHH; set as 1). 
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Figure 2: Re-expression of MIA2 in HCC cells 
Analysis of MIA2 (A) mRNA and (B) protein expression in stable transfected Hep3B 
cell clones (clone 1 and clone 2), mock transfected controls (mock) and non-
transfected cells (wt). controls by quantitative RT-PCR and Western Blotting.  
Primary human hepatocytes (PHH) and recombinant MIA2 protein, respectively, 
served as control. (C) MIA2 was detected by immunofluorescence analysis in the 
Hep3B cell clone 1 (green signal) but not in the Hep3B mock cell clone. Nuclei were 
stained with DAPI (blue). 
 
Figure 3: Effect of MIA2 re-expression or treatment with recombinant MIA2 on 
tumorigenicity of HCC cells in vitro
 
(Hep3B cell clones stably expressing MIA2 (clone 1 and clone 2) and mock 
transfected (mock) and non-transfected (wt) controls were compared in functional in 
vitro assays: (A) Doubling time was determined in proliferation assays. (B) Propidium 
iodide (PI) staining and FACS analysis were applied to investigate cell cycle 
(GO/G1-, S-, and G2/M-phase). (C) Apoptosis was analyzed by FACS analysis of 
Annexin V and propidium iodide (PI) stained cells. (D) The invasive potential was 
assessed by Boyden Chamber assays. 
(E) Doubling time and (F) invasive potential of Hep3B cells treated with recombinant 
MIA2 (rMIA2) and untreated controls. (*: p<0.05). 
 
Figure 4: Tumorigenicity of MIA2 re-expressing HCC cells in vivo
  
(A) Tumour size 15 days after implantation of 1x106 Hep3B cells stably transfected 
with a MIA2 expression plasmid (clone 1 and clone 2), mock transfected (mock) and 
non-transfected control cells into nude mice (n=10/group). (*: p<0.05 compared to 
both wt and mock.) 
(B) HE-staining of tumours derived from MIA2 re-expressing Hep3B cells (I; clone 2) 
and mock transfected cells (II).  
 
Figure 5: Immunohistochemical analysis of MIA2 protein expression in 
human HCC applying tissue microarray (TMA) technology 
(A) Analysis of immunoreactivity for MIA2 of HCC tissues and corresponding non- 
cancerous liver tissue applying a semi quantitative three-step scoring system 
(negative: 0; weak: 1+, and strong: 2+). 
(B) Representative examples of (I) HCC tissue with negative immunoreactivity for 
MIA2 (0), and (II) corresponding non-cancerous liver tissue with strong MIA2 
expression (2+). 
(C)
 Proliferation rate (analyzed by immunohistochemical staining applying anti-Ki67 
antibodies) in HCC-tissues with negative, weak (score 1+), and strong (score 2+) 
MIA2 immunoreactivity. 
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